Renaissance Capital logo

EIDX News

BridgeBio Pharma prices upsized IPO above the range at $17 in year's largest biotech IPO

Eidos Therapeutics logo

BridgeBio Pharma, a late-stage biotech developing therapies for genetic diseases and cancers, raised $349 million by offering 20.5 million shares at $17, above the range of $14 to $16. The company previously filed to offer 20.0 million shares, after first...read more

US IPO Weekly Recap: Biotechs boom in a 13-deal torrent

AUTL

10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more

Rare disease biotech Eidos Therapeutics prices IPO at $17, the high end of the range

Eidos Therapeutics logo

Eidos Therapeutics, which is developing a novel oral therapy for rare neurodegenerative diseases, raised $106 million by offering 6.25 million shares at $17, the high end of the range of $15 to $17. Eidos Therapeutics plans to list on the Nasdaq under the symbol...read more

US IPO Week Ahead: Health care deals lead 11-IPO week

EIDX

Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more